206 related articles for article (PubMed ID: 2548145)
1. Regulation of c-fgr proto-oncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels.
Sharp NA; Luscombe MJ; Clemens MJ
Oncogene; 1989 Aug; 4(8):1043-6. PubMed ID: 2548145
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid induces changes in c-fgr proto-oncogene mRNA levels in Burkitt's lymphoma cells.
Faulkner L; Katz DR; Brickell PM
Immunobiology; 1993 Aug; 188(4-5):460-8. PubMed ID: 8244449
[TBL] [Abstract][Full Text] [Related]
3. fgr proto-oncogene mRNA induced in B lymphocytes by Epstein-Barr virus infection.
Cheah MS; Ley TJ; Tronick SR; Robbins KC
Nature; 1986 Jan 16-22; 319(6050):238-40. PubMed ID: 3003578
[TBL] [Abstract][Full Text] [Related]
4. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
5. Regulation of c-fgr proto-oncogene expression in Epstein-Barr virus infected B-cell lines.
Patel M; Leevers SJ; Brickell PM
Int J Cancer; 1990 Feb; 45(2):342-6. PubMed ID: 2154410
[TBL] [Abstract][Full Text] [Related]
6. Phorbol ester-mediated inhibition of growth and regulation of proto-oncogene expression in the human T cell leukemia line JURKAT.
Makover D; Cuddy M; Yum S; Bradley K; Alpers J; Sukhatme V; Reed JC
Oncogene; 1991 Mar; 6(3):455-60. PubMed ID: 2011401
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
8. Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis.
Kaptein JS; Lin CK; Wang CL; Nguyen TT; Kalunta CI; Park E; Chen FS; Lad PM
J Biol Chem; 1996 Aug; 271(31):18875-84. PubMed ID: 8702548
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-fgr in EBV positive and negative B cell tumors.
Tesch H; Abts H; Jücker M; Mays K; Lenoir G; Diehl V
Leukemia; 1989 Dec; 3(12):897-8. PubMed ID: 2555634
[No Abstract] [Full Text] [Related]
10. Effects of interferon-beta on Daudi cells and on small cell lung carcinoma cells which over-express the c-myc oncogene.
Pape KA; Floyd-Smith G
Anticancer Res; 1989; 9(6):1737-42. PubMed ID: 2560625
[TBL] [Abstract][Full Text] [Related]
11. T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines.
Kiss C; Nishikawa J; Takada K; Trivedi P; Klein G; Szekely L
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4813-8. PubMed ID: 12672960
[TBL] [Abstract][Full Text] [Related]
12. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization.
Knutson JC
J Virol; 1990 Jun; 64(6):2530-6. PubMed ID: 2159528
[TBL] [Abstract][Full Text] [Related]
13. Relationship of cellular oncogene expression to inhibition of growth and induction of differentiation of Daudi cells by interferons or TPA.
Clemens MJ; Tilleray VJ; James R; Gewert DR
J Cell Biochem; 1988 Dec; 38(4):251-9. PubMed ID: 2467914
[TBL] [Abstract][Full Text] [Related]
14. Cloning of the murine c-fgr proto-oncogene cDNA and induction of c-fgr expression by proliferation and activation factors in normal bone marrow-derived monocytic cells.
Yi TL; Willman CL
Oncogene; 1989 Sep; 4(9):1081-7. PubMed ID: 2674853
[TBL] [Abstract][Full Text] [Related]
15. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human B cells and lymphoma B cell lines.
Chaouchi N; Arvanitakis L; Auffredou MT; Blanchard DA; Vazquez A; Sharma S
Oncogene; 1995 Oct; 11(8):1615-22. PubMed ID: 7478586
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of thymidine incorporation and transferrin receptor expression from cell growth and c-myc accumulation in alpha-interferon-treated cells.
Meadows LM; George DJ; Kaufman RE
J Biol Response Mod; 1990 Apr; 9(2):212-20. PubMed ID: 2187953
[TBL] [Abstract][Full Text] [Related]
17. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
18. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
19. Modulation of c-myc oncogene expression by phorbol ester and interferon-gamma: appraisal by flow cytometry.
Mohamed AN; Nakeff A; Mohammad RM; KuKuruga M; al-Katib A
Oncogene; 1988 Oct; 3(4):429-35. PubMed ID: 3152600
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
